Cambridge-based biotechnology company Nuclera has completed its first commercial installations in Asia, deploying eProtein Discovery systems at two leading Taiwanese universities. The National Taiwan University and National Cheng Kung University now have access to the benchtop protein production technology, marking a significant milestone in the company’s global expansion.
Revvity has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions supporting analytical characterisation and molecular design across pharmaceutical and material sciences sectors.
Chitose Laboratory Corp. and FUJIFILM Biosciences Inc. have formed a strategic alliance to advance biopharmaceutical manufacturing by combining CHO-MK cell line technology with GMP-manufactured culture media. The collaboration aims to enhance production efficiency and support the development of therapeutic solutions for the global pharmaceutical industry.
ProteoNic BV has announced that Ginkgo Bioworks has licensed its proprietary 2G UNic vector technology for a $22.2 million project funded by the Biomedical Advanced Research and Development Authority (BARDA). The initiative aims to enhance domestic biomanufacturing capabilities for monoclonal antibodies targeting filovirus infections, including Ebola and Sudan Virus.
ProBioGen has announced a collaboration with Spica Therapeutics to perform cell line development for ST101, a first-in-class monoclonal antibody designed to selectively deplete immunosuppressive CD163+ tumour-associated macrophages in oncology applications.
FineLine Technologies has announced the acquisition of Digi-Trax Corp., a provider of healthcare labelling and identification solutions specialising in blood collection and cellular therapy applications. The deal, announced on 10 December 2025, marks FineLine’s strategic expansion into the healthcare sector and will see Digi-Trax operate as the company’s new Healthcare Division.
EVerZom, a French biotechnology company developing exosome-based therapies for regenerative medicine, has entered into a research collaboration with GENFIT, a biopharmaceutical company specialising in rare liver diseases. The partnership will evaluate EViv, EVerZom’s second proprietary investigational drug candidate, which has been developed to treat acute-on-chronic liver failure (ACLF).
German biotech company T-CURX GmbH has announced the first closing of a $20M (€17.7M) Series A financing round to accelerate clinical development of its non-viral CAR-T cell therapies and advance proprietary in vivo CAR-T generation technologies. The funding round was led by BiomedVC, with participation from Bayern Kapital, HighLight Capital, i&iBio Fund, and existing and […]
The Wellcome Sanger Institute has selected Sapio Sciences’ informatics platform as its central laboratory information management system (LIMS) to support a comprehensive digital transformation programme aimed at unifying genomics workflows across the organisation.
Clinical Experts Issue Special Report Calling for Greater Education, Testing, and Prevention of In Vitro Hemolysis in High-Risk Settings
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
